Annual EBITDA
$8400.00
+$846.10 K+101.00%
31 December 2023
Summary:
China Pharma Holdings annual earnings before interest, taxes, depreciation & amortization is currently $8400.00, with the most recent change of +$846.10 thousand (+101.00%) on 31 December 2023. During the last 3 years, it has fallen by -$98.50 thousand (-92.14%). CPHI annual EBITDA is now -99.97% below its all-time high of $27.77 million, reached on 31 December 2010.CPHI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$386.90 K
+$263.80 K+40.54%
30 September 2024
Summary:
China Pharma Holdings quarterly earnings before interest, taxes, depreciation & amortization is currently -$386.90 thousand, with the most recent change of +$263.80 thousand (+40.54%) on 30 September 2024. Over the past year, it has dropped by -$358.60 thousand (-1267.14%). CPHI quarterly EBITDA is now -103.73% below its all-time high of $10.37 million, reached on 30 September 2008.CPHI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$1.70 M
-$358.60 K-26.66%
30 September 2024
Summary:
China Pharma Holdings TTM earnings before interest, taxes, depreciation & amortization is currently -$1.70 million, with the most recent change of -$358.60 thousand (-26.66%) on 30 September 2024. Over the past year, it has dropped by -$1.67 million (-4910.59%). CPHI TTM EBITDA is now -105.99% below its all-time high of $28.42 million, reached on 31 March 2011.CPHI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPHI EBITDA Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +101.0% | -1267.1% | -4910.6% |
3 y3 years | -92.1% | -280.2% | -630.9% |
5 y5 years | +100.1% | -835.5% | +72.5% |
CPHI EBITDA High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3 years | -96.3% | +101.0% | -236.5% | +40.5% | -839.7% | at low |
5 y | 5 years | -96.3% | +100.0% | -153.3% | +97.8% | -839.7% | +90.5% |
alltime | all time | -100.0% | +100.0% | -103.7% | +98.2% | -106.0% | +95.5% |
China Pharma Holdings EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$386.90 K(-40.5%) | -$1.70 M(+26.7%) |
June 2024 | - | -$650.70 K(+261.7%) | -$1.34 M(+195.7%) |
Mar 2024 | - | -$179.90 K(-63.0%) | -$454.80 K(-5450.6%) |
Dec 2023 | $8400.00(-101.0%) | -$486.10 K(+1617.7%) | $8500.00(-125.0%) |
Sept 2023 | - | -$28.30 K(-111.8%) | -$34.00 K(+20.6%) |
June 2023 | - | $239.50 K(-15.5%) | -$28.20 K(-92.2%) |
Mar 2023 | - | $283.40 K(-153.6%) | -$362.80 K(-56.7%) |
Dec 2022 | -$837.70 K(-463.7%) | -$528.60 K(+2249.3%) | -$837.70 K(+240.9%) |
Sept 2022 | - | -$22.50 K(-76.3%) | -$245.70 K(+2790.6%) |
June 2022 | - | -$95.10 K(-50.3%) | -$8500.00(-124.5%) |
Mar 2022 | - | -$191.50 K(-402.1%) | $34.70 K(-84.9%) |
Dec 2021 | $230.30 K(+115.4%) | $63.40 K(-70.5%) | $230.30 K(-198.8%) |
Sept 2021 | - | $214.70 K(-513.7%) | -$233.10 K(-67.8%) |
June 2021 | - | -$51.90 K(-1365.9%) | -$723.30 K(-1441.9%) |
Mar 2021 | - | $4100.00(-101.0%) | $53.90 K(-49.5%) |
Dec 2020 | $106.90 K(-100.6%) | -$400.00 K(+45.2%) | $106.80 K(-100.6%) |
Sept 2020 | - | -$275.50 K(-138.0%) | -$17.50 M(+1.9%) |
June 2020 | - | $725.30 K(+1172.5%) | -$17.17 M(-3.8%) |
Mar 2020 | - | $57.00 K(-100.3%) | -$17.86 M(+2.3%) |
Dec 2019 | -$17.45 M(+144.1%) | -$18.01 M(<-9900.0%) | -$17.45 M(+182.2%) |
Sept 2019 | - | $52.60 K(+33.2%) | -$6.18 M(-16.1%) |
June 2019 | - | $39.50 K(-91.5%) | -$7.37 M(-0.6%) |
Mar 2019 | - | $464.50 K(-106.9%) | -$7.41 M(+3.6%) |
Dec 2018 | -$7.15 M(-53.3%) | -$6.74 M(+496.3%) | -$7.15 M(-46.0%) |
Sept 2018 | - | -$1.13 M(>+9900.0%) | -$13.24 M(-0.6%) |
June 2018 | - | -$2000.00(-100.3%) | -$13.32 M(-8.9%) |
Mar 2018 | - | $723.00 K(-105.6%) | -$14.62 M(-4.6%) |
Dec 2017 | -$15.32 M(+209.8%) | -$12.83 M(+956.6%) | -$15.32 M(+204.3%) |
Sept 2017 | - | -$1.21 M(-6.8%) | -$5.04 M(+12.3%) |
June 2017 | - | -$1.30 M(-7415.2%) | -$4.48 M(-0.3%) |
Mar 2017 | - | $17.80 K(-100.7%) | -$4.50 M(-9.1%) |
Dec 2016 | -$4.95 M(-53.3%) | -$2.54 M(+284.2%) | -$4.95 M(-34.7%) |
Sept 2016 | - | -$660.60 K(-49.9%) | -$7.58 M(+170.6%) |
June 2016 | - | -$1.32 M(+205.9%) | -$2.80 M(-404.2%) |
Mar 2016 | - | -$430.60 K(-91.7%) | $920.40 K(-164.2%) |
Dec 2015 | -$10.58 M(-71.3%) | -$5.17 M(-225.6%) | -$1.43 M(-91.7%) |
Sept 2015 | - | $4.11 M(+71.3%) | -$17.38 M(-35.8%) |
June 2015 | - | $2.40 M(-186.3%) | -$27.06 M(-28.2%) |
Mar 2015 | - | -$2.79 M(-86.8%) | -$37.67 M(+2.1%) |
Dec 2014 | -$36.90 M(+117.3%) | -$21.11 M(+279.2%) | -$36.90 M(+57.9%) |
Sept 2014 | - | -$5.57 M(-32.2%) | -$23.38 M(+16.0%) |
June 2014 | - | -$8.21 M(+307.4%) | -$20.15 M(+23.2%) |
Mar 2014 | - | -$2.02 M(-73.4%) | -$16.35 M(-3.7%) |
Dec 2013 | -$16.99 M(-330.4%) | -$7.58 M(+223.5%) | -$16.99 M(+63.7%) |
Sept 2013 | - | -$2.34 M(-46.9%) | -$10.37 M(+71.6%) |
June 2013 | - | -$4.41 M(+66.6%) | -$6.04 M(-739.8%) |
Mar 2013 | - | -$2.65 M(+173.3%) | $944.60 K(-87.2%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2012 | $7.37 M(-69.5%) | -$969.20 K(-148.8%) | $7.37 M(-45.0%) |
Sept 2012 | - | $1.99 M(-22.8%) | $13.40 M(-23.7%) |
June 2012 | - | $2.58 M(-31.9%) | $17.57 M(-18.1%) |
Mar 2012 | - | $3.78 M(-25.3%) | $21.46 M(-11.1%) |
Dec 2011 | $24.14 M(-13.1%) | $5.06 M(-17.8%) | $24.14 M(-9.9%) |
Sept 2011 | - | $6.16 M(-4.8%) | $26.80 M(-3.2%) |
June 2011 | - | $6.47 M(+0.1%) | $27.70 M(-2.5%) |
Mar 2011 | - | $6.46 M(-16.3%) | $28.42 M(+2.3%) |
Dec 2010 | $27.77 M(+27.6%) | $7.72 M(+9.3%) | $27.77 M(+16.3%) |
Sept 2010 | - | $7.06 M(-1.9%) | $23.89 M(-5.6%) |
June 2010 | - | $7.19 M(+23.7%) | $25.32 M(+8.9%) |
Mar 2010 | - | $5.81 M(+51.8%) | $23.24 M(+6.8%) |
Dec 2009 | $21.76 M(+6.7%) | $3.83 M(-54.9%) | $21.76 M(-9.6%) |
Sept 2009 | - | $8.48 M(+65.9%) | $24.07 M(-7.3%) |
June 2009 | - | $5.11 M(+18.1%) | $25.96 M(+2.2%) |
Mar 2009 | - | $4.33 M(-29.5%) | $25.41 M(-1.9%) |
Dec 2008 | $20.39 M(+60.9%) | $6.14 M(-40.8%) | $25.89 M(+4.9%) |
Sept 2008 | - | $10.37 M(+127.1%) | $24.68 M(+40.6%) |
June 2008 | - | $4.56 M(-5.2%) | $17.55 M(+6.7%) |
Mar 2008 | - | $4.82 M(-2.3%) | $16.46 M(+29.8%) |
Dec 2007 | $12.67 M(+40.5%) | $4.93 M(+51.9%) | $12.67 M(+20.1%) |
Sept 2007 | - | $3.24 M(-6.4%) | $10.55 M(+11.4%) |
June 2007 | - | $3.47 M(+235.1%) | $9.48 M(+26.9%) |
Mar 2007 | - | $1.03 M(-63.1%) | $7.47 M(-10.8%) |
Dec 2006 | $9.02 M(+100.7%) | $2.81 M(+29.4%) | $8.37 M(+50.4%) |
Sept 2006 | - | $2.17 M(+48.5%) | $5.57 M(+33.7%) |
June 2006 | - | $1.46 M(-24.7%) | $4.17 M(+347.1%) |
Mar 2006 | - | $1.94 M(+153.4%) | $931.70 K(-187.4%) |
Dec 2005 | $4.49 M(-343.9%) | - | - |
Sept 2005 | - | $765.40 K(-143.2%) | -$1.07 M(-42.1%) |
June 2005 | - | -$1.77 M(+4257.7%) | -$1.84 M(+1658.0%) |
June 2005 | -$1.84 M(-576.3%) | - | - |
Mar 2005 | - | -$40.70 K(+133.9%) | -$104.80 K(+72.9%) |
Dec 2004 | - | -$17.40 K(+62.6%) | -$60.60 K(+38.4%) |
Sept 2004 | - | -$10.70 K(-70.3%) | -$43.80 K(-63.5%) |
June 2004 | $386.80 K(-200.9%) | -$36.00 K(-1128.6%) | -$119.90 K(-70.7%) |
Mar 2004 | - | $3500.00(-683.3%) | -$409.70 K(-10.0%) |
Dec 2003 | - | -$600.00(-99.3%) | -$455.30 K(-12.0%) |
Sept 2003 | - | -$86.80 K(-73.4%) | -$517.50 K(+35.0%) |
June 2003 | -$383.40 K(-39.3%) | -$325.80 K(+673.9%) | -$383.40 K(+140.5%) |
Mar 2003 | - | -$42.10 K(-33.0%) | -$159.40 K(-64.0%) |
Dec 2002 | - | -$62.80 K(-232.8%) | -$442.50 K(-0.5%) |
Sept 2002 | - | $47.30 K(-146.5%) | -$444.60 K(-29.6%) |
June 2002 | -$631.50 K | -$101.80 K(-68.7%) | -$631.50 K(+19.2%) |
Mar 2002 | - | -$325.20 K(+401.1%) | -$529.70 K(+159.0%) |
Dec 2001 | - | -$64.90 K(-53.5%) | -$204.50 K(+46.5%) |
Sept 2001 | - | -$139.60 K | -$139.60 K |
FAQ
- What is China Pharma Holdings annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for China Pharma Holdings?
- What is China Pharma Holdings annual EBITDA year-on-year change?
- What is China Pharma Holdings quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for China Pharma Holdings?
- What is China Pharma Holdings quarterly EBITDA year-on-year change?
- What is China Pharma Holdings TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for China Pharma Holdings?
- What is China Pharma Holdings TTM EBITDA year-on-year change?
What is China Pharma Holdings annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of CPHI is $8400.00
What is the all time high annual EBITDA for China Pharma Holdings?
China Pharma Holdings all-time high annual earnings before interest, taxes, depreciation & amortization is $27.77 M
What is China Pharma Holdings annual EBITDA year-on-year change?
Over the past year, CPHI annual earnings before interest, taxes, depreciation & amortization has changed by +$846.10 K (+101.00%)
What is China Pharma Holdings quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of CPHI is -$386.90 K
What is the all time high quarterly EBITDA for China Pharma Holdings?
China Pharma Holdings all-time high quarterly earnings before interest, taxes, depreciation & amortization is $10.37 M
What is China Pharma Holdings quarterly EBITDA year-on-year change?
Over the past year, CPHI quarterly earnings before interest, taxes, depreciation & amortization has changed by -$358.60 K (-1267.14%)
What is China Pharma Holdings TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of CPHI is -$1.70 M
What is the all time high TTM EBITDA for China Pharma Holdings?
China Pharma Holdings all-time high TTM earnings before interest, taxes, depreciation & amortization is $28.42 M
What is China Pharma Holdings TTM EBITDA year-on-year change?
Over the past year, CPHI TTM earnings before interest, taxes, depreciation & amortization has changed by -$1.67 M (-4910.59%)